A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients with Advanced Solid Tumors
NCT #
NCT04706962
Condition(s)
Ovarian/ Peritoneal/ Fallopian Tube Cancer
Molecular Target(s)
Not Required
Drug Classification(s)
peptide-drug conjugate (PDC) which consists of two molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker
Agents(s)
TH1902
Phase(s)
I
Mechanism of Action
TH1902 is docetaxel with a targeting peptide that interacts with Sortilin, a membrane protein overexpressed by many tumors.
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from the study drug
- About the safety of the study drug in participants with advanced solid tumors
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.